Pediatric Growth Concerns Could Hold Corticosteroids Back A Grade
This article was originally published in The Tan Sheet
A reduction of growth rate found in children taking corticosteroids could be the biggest hurdle for sponsors seeking to switch the drugs to over-the-counter status
You may also be interested in...
GlaxoSmithKline CEO Jean-Pierre Garnier called premature a prediction by Schering-Plough CEO Fred Hassan that FDA could approve a nasal-inhaled steroid for over-the-counter use this year
GlaxoSmithKline is actively considering the switch potential for Flonase with a trial evaluating consumers' ability to use the allergy nasal spray appropriately, according to the firm
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC